Division of Oral and Maxillofacial Surgery, Tri-Service General Hospital, Taipei, Taiwan.
School of Dentistry, National Defense Medical Center, Taipei, Taiwan.
Clin Exp Dent Res. 2021 Aug;7(4):409-418. doi: 10.1002/cre2.361. Epub 2020 Dec 1.
To evaluate the efficacy of a novel decellularized porcine bone xenograft, produced by supercritical carbon dioxide extraction technology, on alveolar socket healing after tooth extraction compared to a commercially available deproteinized bovine bone (Bio-Oss®).
Nine dogs (about 18 months old and weighing between 20 kg and 30 kg) underwent extractions of lower second to fourth premolars, bilaterally. The dogs were randomly selected and allocated to the following groups: Group 1: control unfilled socket; Group 2: socket filled with decellularized porcine bone xenograft (ABCcolla®) and covered by a commercially available porcine collagen membrane (Bio-Gide®); Group 3: socket filled with Bio-Oss® and covered by Bio-Gide® membrane. One dogs from each group was sacrificed at 4-, 12-, and 24-week to evaluate the socket healing after tooth extraction. The mandible bone blocks were processed without decalcification and specimens were embedded in methyl methacrylate and subjected to histopathology analyses to evaluate the bone regeneration in the extraction sockets.
At 24-week after socket healing, ABCcolla® treated defects demonstrated significantly higher histopathology score in new bone formation and bone bridging, but significantly lower score in fluorescent labeling than those of the Bio-Oss®. In the microphotographic examination, decellularized porcine bone xenograft showed similar characteristics of new bone formation to that of Bio-Oss®. However, there was significantly less remnant implant materials in the decellularized porcine bone xenograft compared to the Bio-Oss® group at 24-week. Thus, the decellularized porcine bone graft seems to have promising bone regeneration properties similar to that of Bio-Oss® with less remnant grafted material in a canine tooth extraction socket model.
Within the limits of the study, we concluded that ABCcolla® treated defects demonstrated significantly more new bone formation and better bone bridging, but less amount of fluorescent labeling than those of the Bio-Oss® group. However, clinical studies in humans are recommended to confirm these findings.
评估一种新型脱细胞猪骨异种移植物（采用超临界二氧化碳萃取技术制备）在拔牙后牙槽窝愈合方面的疗效，与市售脱蛋白牛骨（Bio-Oss®）相比。
9 只犬（约 18 个月龄，体重 20-30kg）行双侧下颌第二至第四前磨牙拔牙术。随机选择犬并将其分为以下 3 组：第 1 组：未填充牙槽窝的对照；第 2 组：牙槽窝填充脱细胞猪骨异种移植物（ABCcolla®）并用市售猪胶原膜（Bio-Gide®）覆盖；第 3 组：牙槽窝填充 Bio-Oss®并用 Bio-Gide®膜覆盖。每组各有 1 只犬在第 4、12 和 24 周时处死，以评估拔牙后牙槽窝愈合情况。不进行脱钙处理，将下颌骨块加工并包埋在甲基丙烯酸甲酯中，进行组织病理学分析，以评估拔牙窝的骨再生情况。
在牙槽窝愈合后 24 周时，ABCcolla®治疗组的新骨形成和骨桥接的组织病理学评分显著较高，但荧光标记评分显著较低。在显微镜检查中，脱细胞猪骨异种移植物的新骨形成特征与 Bio-Oss®相似。然而，与 Bio-Oss®组相比，在 24 周时，脱细胞猪骨异种移植物中剩余的植入材料明显较少。因此，在犬拔牙窝模型中，脱细胞猪骨移植物具有与 Bio-Oss®相似的有前途的骨再生特性，且剩余的移植物材料较少。
在本研究范围内，我们得出结论，与 Bio-Oss®组相比，ABCcolla®治疗组的新骨形成和骨桥接明显更多，但荧光标记量更少。然而，建议进行人类临床研究以证实这些发现。
